Key Takeaways
- Margin dip, guidance held: EBITDA margin fell to 22.7% from 25.5% YoY on mix and one-offs, yet full-year guidance of 28–30% was reaffirmed.
- Volume engine intact: Revenue growth of 20–24% YoY is sustained by volume scale-up of 8–9 products beyond the top 3–4, with stable pricing.
- Regulatory wedge opening in LatAm: Brazil and Mexico now demand GMP certification that Chinese incumbents cannot provide; Supriya has 12 APIs registered in Brazil and a path to become a permanent first source.
- Innovation pipeline gets tangible: An oral cancer detection kit, a scar-free wound gel, and a plasma nutrition project all moved forward with patents and partnerships, though commercialization is 3 years out.
- What to watch next quarter: Whether the DSM-Firmenich CDMO contract begins delivering commercial volumes, and whether the one-off expenses truly drop out to let margins rebound.
Margin Bridge: The Quarter’s Decline and the Full-Year Bet
- Mix, not geography, drove the erosion: Products beyond the top 3–4 (decongestants, vitamins, antihypertensives) are in a market-gaining phase in semi-regulated markets without leadership positions, so their margin profile is lower. The geographic mix shift was a consequence of this product mix, not an independent driver.
- One-off expenses added ~₹3–4 crores of pressure: A GST audit covering FY2021 (₹26 lakh), a ₹2.5 crore interest cost in a pre-import case contested in Mumbai High Court, and repairs and maintenance tied to an impending December FDA audit all hit the quarter.
- Employee costs stepped up: Annual increments and a couple of previously announced new hires lifted employee benefit expenses.
- The full-year math: Q1 delivered 34%+ EBITDA margin; Q2 dropped to 22.7%. Management argues the H1 average already sits within the 28–30% guided range, and the seasonally stronger second half plus the absence of one-offs will pull the full-year figure into that band.
- Inventory conversion provided a tailwind: WIP and finished goods inventory was converted and sold, with some carryover into Q3; inventory days reduced to 158 days.
Saloni Wagh: "If you actually have attended our earnings call for the last four, five quarters plus you will know that we have corrected our guidance post our impact of the China business in the last financial year. Since then we have corrected our margin guidance to be 28% to 30% which we have maintained and that is the margin that you will see also for the first 6 months."
Growth Drivers: Volume, Basket Expansion, and CDMO
- Volume-led growth with stable prices: Management confirmed prices have remained stable; the majority of growth is through volume increase, though no numerical split was provided.
- A second-tier product basket is scaling: Beyond the top 3–4 products, a basket of 8–9 products (anti-hypertensives, vitamins, decongestants) holds large potential in semi-regulated and regulated markets. Volume scale-up of these products is the current growth engine.
- DSM-Firmenich CDMO agreement adds a new leg: An exclusive vitamin supply agreement was signed with the European giant DSM-Firmenich. Commercial volumes are expected from next quarter, and the broader CDMO pipeline should begin contributing commercially in 9–12 months.
- New product categories in validation: Development is complete on anesthetic, anti-anxiety, and anti-diabetic products; they are now in the validation phase. Some already hold CEPs and US DMFs with small trial quantities supplied; others await CEPs in 6–9 months.
- Plasma nutrition project advancing: Small trial quantities have been manufactured and samples given to larger protein distributors; good commercial volume is anticipated in 6–9 months.
LatAm Regulatory Opportunity: A Structural Shift
- Brazil and Mexico are enforcing GMP for the first time: New regulatory notifications require API suppliers to provide GMP certification. Chinese manufacturers, the sole suppliers for 35–40 years, are failing to produce this documentation.
- Supriya is positioned as the alternative: The company has registered 12 of 16–17 APIs with Brazil’s regulatory authority, positioning as a second vendor that can become a permanent first source once Chinese suppliers are disqualified.
- The opportunity is large and underappreciated: Management noted that the market is ignoring the scale of the Brazil shift, which was entirely served by non-GMP Chinese supply for four decades.
Satish Wagh: "The new regulated market is coming up, which is large in Brazil. People are ignoring that Brazil was catered for last 40 years by China, but all Chinese manufacturer was supplied without GMP standard, GMP documentation and for the first time the government of Brazil has come in 2022 in force that any supplier would like to change the vendor. They should come with the GMP certification from that company."
Innovation Pipeline: Early-Stage, Patent-Protected
- QuickBlue oral cancer detection kit: Two agreements signed with Kalinga Institute of Technology; a patent has been filed for the oral chip. The kit is the cheapest globally, detects oral cancer in under 2–3 minutes, and has no significant competitors. International PCT patents are filed; country-specific patents follow in the next few quarters. The company targets 1–2% market share of the $21.5 billion global cancer market.
- GelHeal wound healing gel: A protein-based cross-link hydrogel using onsite protein matrix technology, developed with Kalinga University. It enables scar-free wound healing with no significant global competitors; patents are filed.
- Commercialization is at least 3 years out: Both the oral cancer kit and the wound healing gel will take a minimum of 3 years to commercialize. Management declined to quantify the investment, stating the full strategy is still being developed.
- Future opportunities are in early exploration: Management is working on multiple innovative opportunities at a premature stage and expressed confidence they will convert into commercial business in 2–3 years.
Saloni Wagh: "There is no product of its time globally, and even for the gel, it is an extremely innovative product which helps in wound healing and scar free wound healing again no significant competitors globally for both the products."
China: Stabilized but Constrained
- Fixed-volume contract, no upside: The China contract for the year is finalized on a fixed-volume basis; no additional volumes are expected. Volumes have stabilized.
- Pricing recovery is distant: Management reiterated that pricing stabilization is not visible in the near future.
- Anti-dumping risk caps strategic appetite: Management explicitly stated it cannot focus on China because of the risk of anti-dumping duties, which would leave the business with no future recourse. The company declined to disclose what proportion of sales China represents.
Satish Wagh: "The day you focus more and more in China, I'm sure you all are aware we are reading in the newspaper anti-dumping duties will be put on the product and there will be no say in the future."
Capex and Capacity: Two Plants, ~₹100 Crores
- Two plants commissioning by March–April: Module-E and the Ambernath plant will both be commissioned around March or April next year. Validations begin first, with commercial operations following immediately for Module-E and around May for Ambernath.
- FY24 capex finalizing at ~₹100 crores: ₹50 crores was already spent in H1. The allocation is primarily for capacity enhancement to support volume growth of the existing product basket and new products being added to the portfolio.
- FY25 capex likely capped at ~₹100 crores: Planning is ongoing; a specific number will be announced next quarter.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 20–24% YoY overall growth | Full year FY24 |
| EBITDA margin | 28–30% full-year margin | Full year FY24 |
| Module-E commissioning | Commissioning, then validations, then commercial operations | March–April 2024 |
| Ambernath plant commercial production | Commercial production start | May 2024 onwards |
| DSM-Firmenich CDMO commercial volumes | Commercial volumes begin | Next quarter (Q3 FY24) |
| Broader CDMO commercial contribution | CDMO pipeline begins contributing commercially | 9–12 months |
| Plasma nutrition commercial volumes | Good commercial volume anticipated | 6–9 months |
| New product CEPs (6–8 products) | CEPs awaited for products targeting regulated markets | 6–9 months |
| Oral cancer kit and wound gel commercialization | Full project commercialization | At least 3 years |
| FY24 capex | ~₹100 crores (₹50 crores spent in H1) | Full year FY24 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue from operations | ₹140 crores, vs ₹112 crores in Q2 FY23 |
| H1 FY24 revenue from operations | ₹272 crores, vs ₹214 crores in H1 FY23 |
| EBITDA | ₹32 crores, vs ₹29 crores in Q2 FY23 |
| EBITDA margin | 22.7%, vs 25.5% in Q2 FY23 |
| H1 FY24 EBITDA margin | 28%, same as H1 FY23 |
| Profit before tax | ₹30 crores, vs ₹27 crores in Q2 FY23 |
| PAT | ₹24 crores, vs ₹17 crores in Q2 FY23 |
| PAT margin | 17% |
| Revenue growth guidance | 20% to 25% overall growth over last year |
| EBITDA margin guidance | 28% to 30% for the full year |
| Export share | 81% of turnover |
| Regulated market share | 46% of sales |
| India share | ~19% of sales |
| Capacity utilization | 72% to 73% during Q2 |
| Inventory days | 158 days, reduced from prior levels |
| One-off expenses in the quarter | ~₹3 crores to ₹4 crores, including GST audit, pre-import case interest, and FDA audit preparation |
| CAPEX, H1 FY24 | ~₹50 crores |
| CAPEX guidance, FY24 | ~₹100 crores total |